Keywords: USA, Drug resistance, Gram-negtive infections, Preferred therapies, Last-resort drugs, Decision Resources

Concerns over drug resistance in Gram-negative infections has led to changes in drug usage in USA

Article | 09 May 2012

Piperacillin-tazobactam is a leading and preferred therapy for Gram-negative infections (GNIs), accounting for a notable share of days of therapy ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in